Ezrin immunohistochemical expression in chondrosarcomas, osteosarcomas and Ewing sarcoma family of tumors

Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma

“…The study cohort contained untreated and treated tumors and included primary tumors (most of the samples) and relapses/recurrences and metastatic tumors as previously described [25,26]. Intact and representative neoplasms on TMAs were confirmed with hematoxylin staining.…”

Ezrin expression predicts local recurrence and development of metastases in soft tissue sarcomas

“…A correlation between ezrin expression and grade has also been reported in chondrosarcoma41 42 and osteosarcoma,43 which could reflect a correlation between ezrin and necrosis. Necrosis represents an important factor in prognostic systems for sarcoma, but difficulties in determining necrosis in core needle biopsies hamper preoperative application 44–47.…”

MicroRNAs in osteosarcoma

“…Its direct target is ezrin, an important member of the ezrin-radixin-moesin (ERM) family. Ezrin functions as a cross-linker between the actin cytoskeleton and the plasma membrane, and is intimately associated with cancers including chondrosarcoma, Ewing's sarcoma and lung cancer [42][43][44]. Studies from our own and other groups have demonstrated that overexpression of ezrin promotes invasion, migration and metastasis of OS cells [45], but ezrin silencing or its small molecule inhibitors NSC305787 and NSC668394 protect against OS development [46,47].…”